Argos Therapeutics sees new promise for immunotherapeutics

Argos Therapeutics believes the success of Seattle-based Dendreon Corp.’s Phase 3 study of immunotherapy PROVENGE, which significantly prolonged the survival of patients with advanced prostate cancer, points out the potential for immunotherapeutics such as... [more]

View complete TechJournal South article